Showing 21 - 40 results of 61 for search '"kidney cancer"', query time: 0.05s Refine Results
  1. 21

    Expanding the miRNA Transcriptome of Human Kidney and Renal Cell Carcinoma by Adam P. Sage, Brenda C. Minatel, Erin A. Marshall, Victor D. Martinez, Greg L. Stewart, Katey S. S. Enfield, Wan L. Lam

    Published 2018-01-01
    “…Despite advancements in therapeutic strategies, diagnostic and prognostic molecular markers of kidney cancer remain scarce, particularly in patients who do not harbour well-defined driver mutations. …”
    Get full text
    Article
  2. 22

    Identification of alterations in the nucleotide sequence of the chromatin remodeling gene PBRM1 in clear cell renal cell carcinoma patients by E. A. Klimentova, I. R. Gilyazova, A. A. Izmailov, I. M. Sultanov, M. A. Bermisheva, V. N. Pavlov, E. K. Khusnutdinova

    Published 2018-11-01
    “…Kidney cancer is a heterogeneous group of malignant tumors, the vast majority of which are renal cell carcinomas (RCC) of various morphological types, of which the most common is the clear cell renal cell carcinoma (ccRCC). …”
    Get full text
    Article
  3. 23

    Surgical treatment of patients with renal cell cancer complicated by specific (tumor) and non-specific thrombosis of the inferior Vena cava by N. V. Vorobev, F. S. Ashyrova, M. P. Golovashchenko, L. O. Petrov, A. D. Kaprin

    Published 2020-09-01
    “…Among malignant neoplasms, kidney cancer occupies one of the first places in terms of the growth rate of incidence in Russia. …”
    Get full text
    Article
  4. 24

    RESULTS OF CLINICAL TRIALS OF MEDICAL TREA TMENT OF RENAL CELL CARCINOMA IN 2014–2015 by A. M. Popov, O. B. Karyakin, A. D. Kaprin

    Published 2016-01-01
    “…In clinical practice, there was a group of targeted drugs, the purpose of which has increased the life expectancy of patients with advanced kidney cancer. The studies devoted to the study of the sequence of destination targeted agents, combinations, studies of new drugs and to identify prognostic factors, are held.…”
    Get full text
    Article
  5. 25

    The Impact of Immune System in Regulating Bone Metastasis Formation by Osteotropic Tumors by Lucia D’Amico, Ilaria Roato

    Published 2015-01-01
    “…Bone metastases are frequent and debilitating consequence for many tumors, such as breast, lung, prostate, and kidney cancer. Many studies report the importance of the immune system in the pathogenesis of bone metastasis. …”
    Get full text
    Article
  6. 26

    Interaction among Cells of Bone, Immune System, and Solid Tumors Leads to Bone Metastases by Ilaria Roato

    Published 2013-01-01
    “…Bone metastases are a dismal consequence for different types of solid tumors, such as breast, prostate, lung, and kidney cancer. The mechanisms regulating the interactions among bone, immune system, and tumor cells have been deeply investigated, and many studies are ongoing to define the specific role of the different cells in the bone metastatic process. …”
    Get full text
    Article
  7. 27

    Statistical identification of cell type-specific spatially variable genes in spatial transcriptomics by Lulu Shang, Peijun Wu, Xiang Zhou

    Published 2025-01-01
    “…Applied to five real datasets, Celina uncovers ct-SVGs associated with tumor progression and patient survival in lung cancer, identifies metagenes with unique spatial patterns linked to cell proliferation and immune response in kidney cancer, and detects genes preferentially expressed near amyloid-β plaques in an Alzheimer’s model.…”
    Get full text
    Article
  8. 28

    Cabozantinib Cutaneous Toxicity—Comprehensive Review by Cristina Violeta Tutunaru, Dragos Ovidiu Alexandru, Sanda Amelia Dracea, Loredana Ungureanu, Liliana Gabriela Popa, Cristina Beiu

    Published 2025-01-01
    “…This review offers an overview of the skin-related toxicities associated with Cabozantinib, a multikinase inhibitor (MKI) that is approved for treating advanced kidney cancer, hepatocellular carcinoma, and medullary thyroid cancer. …”
    Get full text
    Article
  9. 29

    Cytomegalovirus Infection in Patient with Clear Cell Renal Cell Carcinoma by Ikhwan Rinaldi, Abdul Muthalib, Januar Widodo Sutandar, Hendro Adi Kuncoro, Bambang Irawan Harsono, Nelly Susanto, Tjondro Setiawan, Kevin Winston, Idham Rafly Dewantara, Ihya Fakhrurizal Amin, Yuli Maulidiya Shufiyani

    Published 2023-01-01
    “…While there have been several studies on CMV infection in post-transplant patients, there is limited literature on CMV infection in cancer, particularly in kidney cancer. Case Report. In this case report, we present the case of a 61-year-old man with clear cell renal cell carcinoma who underwent targeted therapy with the receptor tyrosine kinase (RTK) inhibitor lenvatinib and the mammalian target of rapamycin (mTOR) inhibitor everolimus. …”
    Get full text
    Article
  10. 30

    Identifying ADME-related gene signature for immune landscape and prognosis in KIRC by single-cell and spatial transcriptome analysis by Hongyun Wang, Feizhou Li, Qiong Wang, Xinyuan Guo, Xinbing Chen, Xinrong Zou, Jun Yuan

    Published 2025-01-01
    “…Abstract Kidney renal clear cell carcinoma (KIRC) is the most prevalent subtype of kidney cancer. Although multiple therapeutic agents have been proven effective in KIRC, their clinical application has been hindered by a lack of reliable biomarkers. …”
    Get full text
    Article
  11. 31

    ANALYSIS OF THE INTRAOPERATIVE ULTRASOUND RESULTS IN THE SURGICAL TREATMENT OF RENAL TUMORS by A. D. Karnin, A. A. Kostin, S. O. Stepanov, N. V. Vorobyev, P. D. Bespalov, V. O. Dimitrov

    Published 2019-04-01
    “…Possibilities of IOUS application in the surgical treatment of kidney tumor according to the results of examination and surgical treatment of 145 patients (95 men and 50 women) diagnosed with kidney cancer were evaluated. The patients were divided into 2 groups: group 1 (comparisons) — 76 patients; during the examination and treatment, the IOUS method was not used, group 2 (basic) — 69 patients, who during the surgical treatment used the IOUS method to further clarify the localization, the size and boundaries of the tumor formation.Results. …”
    Get full text
    Article
  12. 32

    Investigation of CD47 Expression in Renal Cell Tumors and Evaluation of Its Relationship with Prognostic Parameters by Ömer Faruk Dizibüyük, Zehra Bozdağ, Metin Karakök

    Published 2024-12-01
    “…<b>Background/Objectives:</b> Renal cell carcinoma is an aggressive form of kidney cancer, contributing to an estimated 138,000 deaths globally in 2017. …”
    Get full text
    Article
  13. 33

    Serum Matrix Metalloproteinases and Risk of Urologic Cancers: A Bidirectional Mendelian Randomization Study by BoWen Yang, XiaoYu Zeng, HanYu Wang, JiuHuan Feng, ShuFang Hou

    Published 2025-02-01
    “…We did not find significant associations of the remaining MMPs with prostate, bladder, and kidney cancer. In reverse MR, no significant results were observed supporting the effect of urologic cancers on MMPs ( p > .05). …”
    Get full text
    Article
  14. 34

    AURKB affects the proliferation of clear cell renal cell carcinoma by regulating fatty acid metabolism by Yang Yang, Dan Li, Zhigang Liu, Kai Zhou, Wenxing Li, Yanqi Yang, Ruifang Sun, Yulong Li

    Published 2025-01-01
    “…Abstract Background Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer with a high metastatic rate and high mortality rate. …”
    Get full text
    Article
  15. 35

    Health risks evaluation of mycotoxins in plant-based supplements marketed in Malaysia by Rozaini Abdullah, Nur Syazwin Kamarozaman, Siti Soleha Ab Dullah, Mohd Yusmaidie Aziz, Hussein Bakheit Adam Aziza

    Published 2025-01-01
    “…A quantitative cancer risk assessment also estimated the percentage of hepatocellular carcinoma and kidney cancer attributable to mycotoxin exposure. The findings emphasize the significant public health risks posed by mycotoxins, particularly in samples B2 and B10, where all three mycotoxins studied were present at concerning levels. …”
    Get full text
    Article
  16. 36

    Cancer Stem Cell Marker Endoglin (CD105) Induces Epithelial Mesenchymal Transition (EMT) but Not Metastasis in Clear Cell Renal Cell Carcinoma by Junhui Hu, Wei Guan, Libin Yan, Zhangqun Ye, Lily Wu, Hua Xu

    Published 2019-01-01
    “…Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of kidney cancer. We previously reported that CD105(+) subpopulation in human ccRCC tumors possesses tumor cell self-renewal and chemoresistance capability. …”
    Get full text
    Article
  17. 37

    APOBEC3C‐mediated NF‐κB activation enhances clear cell renal cell carcinoma progression by Nora Hase, Danny Misiak, Helge Taubert, Stefan Hüttelmaier, Michael Gekle, Marcel Köhn

    Published 2025-01-01
    “…Renowned as the predominant form of kidney cancer, clear cell renal cell carcinoma (ccRCC) exhibits susceptibility to immunotherapies due to its specific expression profile as well as notable immune cell infiltration. …”
    Get full text
    Article
  18. 38

    Identification of hub genes, non-coding RNAs and pathways in Renal cell carcinoma (RCC): A comprehensive in silico study by Ahmad Golestanifar, Hengameh Khedri, Parisa Noorabadi, Mohammadreza Saberiyan

    Published 2025-03-01
    “…Backgrounds: Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults. RCC begins in the renal tubule epithelial cells, essential for blood filtration and urine production. …”
    Get full text
    Article
  19. 39

    Comprehensive analysis of the prognostic, immunological, and diagnostic roles of SIRT1 in pan-cancer and its validation in KIRC by Qi Liu, Songxian Sun, Chunxiang Zhou, Houxi Xu, Houxi Xu

    Published 2025-01-01
    “…Furthermore, we validated the differential expression of SIRT1 in normal human kidney cells and kidney cancer cell lines via experimental verification.ResultsSIRT1 expression was significantly reduced in various cancers and was different across molecular and immune subtypes. …”
    Get full text
    Article
  20. 40

    The COVID‐19 pandemic and associated declines in cancer incidence by race/ethnicity and census‐tract level SES, rurality, and persistent poverty status by Benmei Liu, Mandi Yu, Jeffrey Byrne, Katheen A. Cronin, Eric J. Feuer

    Published 2024-09-01
    “…Significantly larger PCs were observed for the lowest versus highest SES groups (prostate cancer), PP versus non‐PP groups (prostate and female breast cancer), and all urban versus rural areas (prostate, female breast, female and male lung, colon, cervix, melanoma, liver, bladder, and kidney cancer). Conclusions The COVID‐19 pandemic coincided with reduction in incidence rates in the U.S. in 2020 and was associated with worsening disparities among groups, including race/ethnicity, SES, rurality, and PP groups, across most cancer sites. …”
    Get full text
    Article